So Covid-19 leader BioN­Tech has a can­cer vac­cine in de­vel­op­ment? Yes, and Re­gen­eron just jumped in for the PhII com­bo study

Be­fore the coro­n­avirus glob­al emer­gency stole the R&D show in bio­phar­ma, the lead­ers in the race to de­vel­op new mR­NA ther­a­pies had a big in­ter­est in de­ter­min­ing if their tech could be used to cre­ate an ef­fec­tive can­cer vac­cine af­ter all the first-gen tries had failed to im­press. So per­haps it’s not sur­pris­ing that an ear­ly cut of the da­ta at fron­trun­ner BioN­Tech went large­ly un­no­ticed.

Un­less you were at Re­gen­eron.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.